All articles tagged with #kj muldoon
KJ Muldoon, the first patient to receive a personalized CRISPR gene editing therapy for severe CPS1 deficiency, was discharged after successful treatment, marking a significant milestone in rapid, customized treatment for rare genetic disorders and highlighting the potential for scalable, patient-specific gene therapies.
KJ Muldoon became the first person to receive a personalized gene-editing therapy using base editing technology to treat a rare genetic disorder, CPS1 deficiency, just six months after diagnosis, demonstrating a groundbreaking advance in personalized medicine for untreatable rare diseases.
A 6-month-old named KJ Muldoon received a personalized CRISPR gene editing treatment that improved his condition, offering hope for the struggling gene editing industry which has faced setbacks in recent years. The success highlights the potential of gene editing technology to treat complex diseases, reigniting optimism in the biotech sector.